Showing results (2181-2190 of 2,239) with videos related to
Sort By:
Pageof 224
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trialQing Zhou, Ming Chen, Ou Jiang, et al.Nature Plants|January 16, 2023
A natural allele of proteasome maturation factor improves rice resistance to multiple pathogensXiao-Hong Hu, Shuai Shen, Jin-Long Wu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2023
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical OutcomesChang Lu, Xue-Wu Wei, Zhen Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung CancerGlenwood D Goss, Gail E Darling, Virginie Westeel, et al.The Lancet. Oncology|November 28, 2017
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyWen-Zhao Zhong, Qun Wang, Wei-Min Mao, et al.Journal of Cancer Research and Clinical Oncology|June 14, 2023
Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS studyQing Zhou, He-Long Zhang, Li-Yan Jiang, et al.Targeted Oncology|January 12, 2022
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in ChinaHai-Yan Tu, Jifeng Feng, Meiqi Shi, et al.Pageof 224